Clinical trial · Interventional
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)
NCT06856278CI-TRIAL-00086737not yet recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaplastic Throid Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NKG2D CAR-NK with PD-1 Antibody | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
- interventionNames
- Drug: NKG2D CAR-NK with PD-1 Antibody
Primary outcomes (1)
- measure
- Safety and tolerability
- timeFrame
- From the start of the trial to day 56 after the first infusion of CAR-NK.
- description
- Safety and tolerability at 28 days after combination therapy, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) were determined.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-75 years (including boundary values), male or female. 2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm. 3. Liver and kidney function is good, and can tolerate treatment. 4. Be able to cooperate with the completion of treatment and follow-up work. 5. No other systemic diseases, including other malignancies. Exclusion Criteria: 1. Need to breastfeed the baby or have fertility needs； 2. Immune system diseases; 3. Diseases of the blood system; 4. Mental system diseases; 5. Interstitial pneumonia, lung disease, etc.; 6. Failure to follow rules of this study.
References
Publications (0)
Data not yet available
No reference posted for this study.